A newly approved combination of acalabrutinib plus venetoclax is giving people with newly diagnosed chronic lymphocytic leukemia (CLL) another chemotherapy-free option that is taken for a fixed period ...

Imbruvica is a prescription drug used in adults with chronic lymphocytic leukemia (CLL), a type of cancer that starts in the bone marrow. The drug is available in three oral forms: a capsule, tablet, ...

Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...

Brukinsa (zanubrutinib) is a brand-name oral tablet prescribed for chronic lymphocytic leukemia (CLL) and certain other cancers. It works by blocking an enzyme called Bruton’s tyrosine kinase (BTK) ...

BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL). These targeted medications block a protein called Bruton’s tyrosine kinase (BTK), which helps CLL cells survive and ...

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...

The FDA approved acalabrutinib (Calquence) plus venetoclax (Venclexta) for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma as the first all-oral, fixed-duration ...

Not long ago, treatment for chronic lymphocytic leukemia (CLL) often meant needing chemotherapy or a targeted medication for the rest of your life, as long as you tolerated it and your doctor could ...

As a healthy 50-year-old, Cindy expected a routine doctor’s visit. She had swollen lymph nodes and assumed it was something minor, like a lingering infection. Instead, she received news that would ...